Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08JSJ
|
||||
| Former ID |
DNC005711
|
||||
| Drug Name |
4-(4-p-Tolylamino-phthalazin-1-yl)-benzamide
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [527725] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C22H18N4O
|
||||
| Canonical SMILES |
CC1=CC=C(C=C1)NC2=NN=C(C3=CC=CC=C32)C4=CC=C(C=C4)C(=O)N
|
||||
| InChI |
1S/C22H18N4O/c1-14-6-12-17(13-7-14)24-22-19-5-3-2-4-18(19)20(25-26-22)15-8-10-16(11-9-15)21(23)27/h2-13H,1H3,(H2,23,27)(H,24,26)
|
||||
| InChIKey |
UTDXGHMGCXLCKT-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Vascular endothelial growth factor receptor 2 | Target Info | Inhibitor | [527725] | |
| NetPath Pathway | IL2 Signaling Pathway | ||||
| PANTHER Pathway | Angiogenesis | ||||
| VEGF signaling pathway | |||||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
| Beta3 integrin cell surface interactions | |||||
| Signaling events mediated by TCPTP | |||||
| SHP2 signaling | |||||
| S1P1 pathway | |||||
| VEGF and VEGFR signaling network | |||||
| Integrins in angiogenesis | |||||
| Signaling events mediated by VEGFR1 and VEGFR2 | |||||
| Notch-mediated HES/HEY network | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.